Royal Philips introduced two new balloons to its Stellarex 0.035-inch low-dose drug-coated balloon (DCB) portfolio. The new 200mm and 150mm Stellarex 0.035-inch low-dose DCBs have received approval from the U.S. Food and Drug Administration (FDA) for the treatment of de novo and restenotic lesions in native superficial femoral or popliteal arteries, both arteries in the upper leg. The new balloons broaden physicians’ treatment options for peripheral artery disease (PAD) patients with a high risk of restenosis. The 200mm and 150mm Stellarex 0.035-inch low-dose DCBs are now available in the U.S. and will be rolled out to other markets in due course.

October 15, 2019 — Kardium Inc. announced that the Globe mapping and ablation system has successfully demonstrated ...

Medtronic plc announced the start of a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system to treat dangerously fast heart rhythms. The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional, transvenous ICDs, but with a lead (thin wire) placed outside the heart and veins.

October 10, 2019 — An independent analysis of Lutonix 035 drug-coated balloon (DCB) patient-level data showed no ...

In the complex and fast-paced world of healthcare, customers face the challenge of staying up-to-date with the most advanced systems while also keeping costs down. Providers now have a solution from Canon Medical Systems USA: the Alphenix Encore Plus Program. The program enables customers to upgrade their aging angiography systems to the latest technology while maintaining many existing parts, delivering clinical excellence, operational continuity and cost savings.